Your SlideShare is downloading. ×
0
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

TheQuestionoftheUseOfPsychiatricPharmaceuticalsInPediatrics

2,652

Published on

This are the slides used by Barry in his presentation at the Vatican. The presentation asked if the clinical trial evidence supports the global rising of prescriptions to youth. The answer is an …

This are the slides used by Barry in his presentation at the Vatican. The presentation asked if the clinical trial evidence supports the global rising of prescriptions to youth. The answer is an unequivoval "NO." Guidelines are offered for prescriptive practice to youth.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
2,652
On Slideshare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
11
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. The Question of the Use of Psychiatric Pharmaceuticals in Paediactrics Pope Benedict XVI: “Scientific predictability also raises the question of the scientists’ ethical responsibilities...Certainly this means avoiding needlessly alarming predictions when these are not supported by sufficient data…But it also means avoiding the opposite, namely a silence born of fear, in the face of genuine problems.”
  • 2. Children and Prescription Rates Increasing Globally  In the US, spending for meds for child behavior problems eclipsed any other drug category, including antibiotics  While the US leads the world in psychiatric prescriptions to youth, global use of ADHD drugs has increased by 274% and antipsychotics have doubled across Europe
  • 3.  The number of youth taking 1 or more psychiatric medicines has hit nearly 9% in the US, 6% in the UK, and 3% in Australia—although not one clinical trial has examined polypharmaceutical intervention with children Children and Prescription Rates Increasing Globally
  • 4. Study of poor children found that 26% on antipsychotics; Poor children 4 times more likely to be on antipsychotics 57% of foster children are taking 3 or more psychiatric drugs, 6 times national average •Children in state custody greatest predictor of psychotropic drug use •Children in foster care 16 times more likely to be medicated…Gabriel
  • 5. Gabriel Was a Foster Child Gabriel was on Vyvance for ADHD, Lexapro, an antidepressant, Zyprexa, an antipsychotic, Symbyax, also an antidepressant, and Adderal for ADHD. 7 year old Gabriel hung himself on April 19
  • 6. The Questions Children and Psychiatric Drugs  Are the skyrocketing rates of prescription justified by clinical trial evidence?  Are physicians who prescribe psychotropic medications following the scientific mandates of evidence based medicine?
  • 7.  Are children, by virtue of their powerless & dependent position, victims of an industry motivated by greed rather than science & ethics?  Are the differential rates of prescription of psychiatric drugs to poor children a violation of equitable & human health care? The Questions Children and Psychiatric Drugs
  • 8. Antidepressants The Evidence Of 15 published and unpublished clinical trials, only 3 show superiority to placebo on primary measures; none on patient or parent measures. Antidepressants carry at least double the chance for suicidal ideation and behavior…Black box warning…Nicole
  • 9. Emslie Trials: Two of the 15 Finding No Difference on Primary Measures  8 and 9 week RCTs  Placebo-controlled  Double-blind  Compared fluoxetine (Prozac) and placebo  Concluded that Prozac was superior to placebo and FDA approval followed
  • 10. The Emslie Studies  Both studies proclaim Prozac “well tolerated” and safe.  Failed to discuss the 6% dropout due to manic (akathisia) reactions (3 x placebo) or double suicidal rate.
  • 11. The Multimodal Treatment Study of Children with ADHD (MTA)  Large 14 mo comparison of managed med v. BT v. combined v. TAU (medicated)  19 outcome measures  All 4 groups improved  Concluded that MM superior to BT & Combined brought no advantages
  • 12. Stimulants MTA: The Evidence Found advantage to med group on 3 of 19 measures At 36 months, tx groups did not differ.
  • 13. Stimulants The MTA Adverse Events  64% of the children experienced ADRs; 11% were rated as moderate, and 3% as severe.  Follow-up reveals sig. growth reduction with no rebound
  • 14. Treatment of Early Onset Schizophrenia Spectrum Disorders  TEOSS compared two SGAs (Risperdal & Zyprexa) to a FGA (Moban).  At the end of eight weeks, the “response” rate was 50% for those treated with Moban, 46% for Risperdal, and 34% for Zyprexa; 41% didn’t complete 8 weeks.
  • 15. TEOSS Suicide  1 suicide & 8 (8%) were hospitalized for suicidality or worsening psychosis—at risk excluded.  Weight gain resulted in suspension of Zyprexa arm.  Adverse events “frequent.” “May place many youth at risk for diabetes and cardiovascular problems.”
  • 16. Sparks, Duncan, Cohen, & Antonuccio, Fatal Flaws to Watch For  Given the infiltration of industry influence, discerning good science from good marketing requires a willingness to engage primary sources  Flaws cast doubt on claims that medication should be a first line solution for any problem.
  • 17. Fatal Flaws of Drug Studies Patient versus Clinician Ratings  Patients & clinicians differ on impressions of improvement  Outcome measures are most often clinician-rated  When patient ratings are used, no difference results  If patients don’t know they’re better, how much better are they? You are feeling better!
  • 18. Patient versus Clinician Ratings Emslie, MTA ,TEOSS  Emslie: No difference on patient rated measures  MTA: No difference on only blinded measure (blinded classroom raters); and on the child’s rating & peer’s rating  TEOSS: Used no patient rated measure; minimal improvement counted as response on PANSS
  • 19. Fatal Flaws of Drug Studies Time of Measurement  Medications are never prescribed for short periods of time  8-12 week trials inadequately determine effect; differences start to dissolve by 16 weeks  Drug trial time frames: logistics or strategy?
  • 20. Time of Measurement Emslie, MTA, TEOSS  Emslie studies 8 & 9 weeks  MTA endpoint at 14 months; but BT was discontinued up to 6 mos before endpoint measurement! Comparison was med v. withdrawn BT, making the finding that only 3 measures superior even more amazing  TEOSS: Long term follow up revealed only 12% responded to treatment
  • 21. Time of Measurement TEOSS  The 54 who “responded” during the initial 8 weeks entered into the 44-week maintenance study  40 of 54 dropped out because of “adverse effects” or “inadequate response.” Only 14 of 116 youth responded and stayed on it for as long as one year—only 12%.
  • 22. Because of industry influence, most journals now attempt transparency regarding funding sources & author affiliations. With these as caveats, readers can approach the study with a warranted skepticism & a more careful analysis of trial methods & conclusions. Fatal Flaws of Drug Studies Conflicts of Interest
  • 23. Conflicts of Interest Emslie, MTA, & TEOSS  Emslie: Emslie & Wagner paid consultants for Eli Lilly, the funders. Other 6 listed as employees and “may own stock in that company.”  MTA: Lead investigator, Peter Jensen, and five other authors have ties to pharmaceuticals; Jensen is a consultant to Novartis, the makers of Ritalin, the drug in the MTA.  TEOSS: Lead investigators paid consultants of the makers of the antipsychotic meds used in TEOSS
  • 24. Fatal Flaws of Drug Studies Minimization of Risks  Lack of standardized measures for adverse events; mostly from spontaneous report   Rhetoric obscures data; Conclusions for tolerability and safety do not reflect findings This won’t hurt a bit
  • 25. Psychiatric Drugs The Risks That Don’t Make the Ads Antidepressant Risks: Mania—5 times the rate of placebo; ‘Warning’ for suicidal behavior—twice the rate of placebo; stunted growth Stimulant Risks: ‘Warnings’ for suicide and cardiac risk; loss of 1 cm and 2.7 kg per yr; Mania, psychosis, cardiac sudden death; 64% report adverse reactions Antipsychotic Risks: Diabetes, obesity; EPS, tardive dyskinesia, neuroleptic malignant syndrome, suicide, akathisia A risk/benefit analysis does not support drugs as a 1st line treatment.
  • 26. In a Study of Risperidone Reyes et al. (2006) Assert: “Risperidone has consistently demonstrated efficacy and safety in both controlled short-term and open-label long-term studies” (p. 402). Five studies are cited to back this claim—two short-term and three, longer-term
  • 27. Besides Somnolence, Elevated Serum Prolactin, Weight Gain, EPS, and TD  Overall, 76 of the 77 participants in Turgay et al. reported adverse events, close to 92% in Croonenberghs et al., and nearly 91% in Findling et al.  Yet, all report: “generally safe” and “well tolerated” in every abstract and conclusion
  • 28. Conclusions Practices Antithetical to EBM  When clinical trials are critically examined…the evidence does not support drug treatments as a first line intervention.  Knowing that there is no compelling evidence to medicate, we are free to discuss the risks/benefits & other alternatives: Church, community, counseling to help families choose in concert w/ values, culture, & preferences. Bottom Line: Look at the evidence yourself and draw your own conclusions
  • 29. Where Children Are Concerned The Stakes Are Higher Do not have a voice to say no & depend on adults to safeguard wellbeing; poor children have fewer adults watching over them & are vulnerable to dangerous drugs used for control rather than therapy, and therefore require more to ensure equitable care.
  • 30. The Evidence and Ethics Demand A Higher Standard of Equitable Care 1) Psychosocial intervention first—especially to the poor 2) No off label prescribing; 3) No polypharmacy 4) Separate pharmaceutical company influence from science and practice 5) Monitor treatment response with patient rated measures
  • 31. The Church In Addition to Spiritual Leadership  Has a rich history of benefiting humanity, comforting the frail and disenfranchised, protecting the sanctity of human life, and strengthening families. The Church may be the only power on earth that can counter the forces of corporate greed that have no moral or ethical conscience.
  • 32.  Accurate data & solutions that value family, Church,& community  Education of health/ pastoral professionals to enable risk/benefit discussions  Prevention of spread of practices that are greed motivated not evidence based—a call to action to participants…Nicole For There To Be Social Justice For There To Be Equitable Care
  • 33. Although a clinical trial will never address it The use of psychiatric drugs in paediatrics begs yet another question: Do these drugs interfere with spiritual development, the voice of the soul, and one's ability to commune with the Divine?

×